Hereditary angioedema in childhood: An approach to management

Pediatric Drugs

Volumn 12, Issue 4, 2010, Pages 257-268

  Ebo, Didier G ^a   Verweij, Marjoke M ^a   De Knop, Kathleen J ^a   Hagendorens, Margo M ^a   Bridts, Chris H ^a   De Clerck, Luc S ^a   Stevens, Wim J ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

antifibrinolytic agents, therapeutic use; bradykinin B2 receptor antagonists, therapeutic use; children; complement C1r inhibitors, therapeutic use; ecallantide, therapeutic use; hereditary angioedema, pathogenesis; hereditary angioedema, prevention; hereditary angioedema, treatment; icatibant, therapeutic use; kallikrein inhibitors, therapeutic use; research and development; testosterone congeners, therapeutic use

Indexed keywords

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; CETOR; COMPLEMENT COMPONENT C1S INHIBITOR; DANAZOL; ECALLANTIDE; FRESH FROZEN PLASMA; ICATIBANT; OXANDROLONE; STANOZOLOL; TRANEXAMIC ACID; UNCLASSIFIED DRUG;

ANGIONEUROTIC EDEMA; CHILDHOOD DISEASE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; MAINTENANCE THERAPY; PATIENT EDUCATION; PATIENT INFORMATION; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW;

ANGIOEDEMAS, HEREDITARY; ANIMALS; CHILD; HEALTH EDUCATION; HUMANS; TIME FACTORS;

EID: 77954525383     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.2165/11532590-000000000-00000     Document Type: Review

References (124)

1. Quincke H. Concerning the acute localized oedema of the skin. Monatsh Prakt Derm 1882; 1: 129-131
2. Osler W. Hereditary angio-neurotic oedema. Am J Med Sci 1888; 95: 362-367
3. Crowder JR, Crowder TR. Five generations of angioneurotic oedema. Arch Intern Med 1917; 20: 840-852
4. Verpy E, Biasotto M, Brai M, et al. Exhaustive mutation scanning by fluorescence-assisted mismatch analysis discloses new genotype-phenotype correlations in angiodema. Am J Hum Genet 1996; 59: 308-319
5. Bissler JJ, Aulak KS, Donaldson VH, et al. Molecular defects in hereditary angioneurotic edema. Proc Assoc Am Physicians 1997; 109: 164-173
6. Kalmar L, Hegedus T, Farkas H, et al. HAE: a novel interactive, locus-specific mutation database for the C1 inhibitor gene. Hum Mutat 2005; 25: 1-5
7. Laimer M, Klausegger A, Aberer W, et al. Haploinsufficiency due to deletion within the 3'-UTR of C1-INH-gene associated with hereditary angioedema. Genet Med 2006; 8: 249-254
8. Pappalardo E, Caccia S, Suffritti C, et al. Mutation screening of C1 inhibitor gene in 108 unrelated families with hereditary angioedema: functional and structural correlates. Mol Immunol 2008; 45: 3536-3544
9. Gosswein T, Kocot A, Emmert G, et al. Mutational spectrum of the C1INH (SERPING1) gene in patients with hereditary angioedema. Cytogenet Genome Res 2008; 121: 181-188
10. Nzeako UC, Frigas E, Tremaine WJ. Hereditary angioedema: a broad review for clinicians. Arch Intern Med 2001; 161: 2417-2429
11. Donaldson VH, Evans RR. A biochemical abnormality in hereditary angioneurotic edema: absence of serum inhibitor of C1-esterase. Am J Med 1963; 35: 37-44
12. Schreiber AD, Kaplan AP, Austen KF. Inhibition by C1INH of Hagemann factor fragment activationof coagulation, fibrinolysis, and kinin generation. J Clin Invest 1973; 52: 1402-1409
13. Davis III AE. C1 inhibitor and hereditary angioneurotic edema. Annu Rev Immunol 1988; 6: 595-628
14. Nielsen EW, Johansen HT, Hogasen K, et al. Activation of the complement, coagulation, fibrinolytic and kallikrein-kinin systems during attacks of hereditary angioedema. Scand J Immunol 1996; 44: 185-192 (Pubitemid 26246739)
15. Cugno M, Cicardi M, Bottasso B, et al. Activation of the coagulation cascade in C1-inhibitor deficiencies. Blood 1997; 89: 3213-3218
16. Davis III AE. Mechanism of angioedema in first complement component inhibitor deficiency. Immunol Allergy Clin North Am 2006; 26: 633-651
17. Agostoni A, Ygoren-Pursun E, Binkley KE, et al. Hereditary and acquired angioedema: problems and progress. Proceedings of the Third C1 Esterase Inhibitor Deficiency Workshop and Beyond. J Allergy Clin Immunol 2004; 114: S51-131
18. Cicardi M, Zingale LC. The deficiency of C1 inhibitor and its treatment. Immunobiology 2007; 212: 325-331
19. Davis III AE. Hereditary angioedema: a current state-of-the-art review. III: mechanisms of hereditary angioedema. Ann Allergy Asthma Immunol 2008; 100: S7-12
20. Joseph K, Tuscano TB, Kaplan AP. Studies of the mechanisms of bradykinin generation in hereditary angioedema plasma. Ann Allergy Asthma Immunol 2008; 101: 279-286
21. Schachter M, Uchida Y, Longridge DJ, et al. New synthetic antagonists of bradykinin. Br J Pharmacol 1987; 92: 851-855
22. Whalley ET, Nwator IA, Stewart JM, et al. Analysis of the receptors mediating vascular actions of bradykinin. Naunyn Schmiedebergs Arch Pharmacol 1987; 336: 430-433
23. Han ED, MacFarlane RC, Mulligan AN, et al. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest 2002; 109: 1057-1063
24. Bas M, Adams V, Suvorava T, et al. Nonallergic angioedema: role of bradykinin. Allergy 2007; 62: 842-856
25. Byrd JB, Adam A, Brown NJ. Angiotensin-converting enzyme inhibitorassociated angioedema. Immunol Allergy Clin North Am 2006; 26: 725-737
26. Bork K, Barnstedt SE, Koch P, et al. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet 2000; 356: 213-217
27. Binkley KE, Davis III A. Clinical, biochemical, and genetic characterization of a novel estrogen-dependent inherited form of angioedema. J Allergy Clin Immunol 2000; 106: 546-550
28. Dewald G, Bork K. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Commun 2006; 343: 1286-1289
29. Cichon S, Martin L, Hennies HC, et al. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am J Hum Genet 2006; 79: 1098-1104
30. Farsetti A, Misiti S, Citarella F, et al. Molecular basis of estrogen regulation of Hageman factor XII gene expression. Endocrinology 1995; 136: 5076-5083
31. Colman RW. Surface-mediated defense reactions: the plasma contact activation system. J Clin Invest 1984; 73: 1249-1253
32. Cicardi M, Bergamaschini L, Zingale LC, et al. Idiopathic nonhistaminergic angioedema. Am J Med 1999; 106: 650-654
33. Gupta S, Yu F, Klaustermeyer WB. New-variant hereditary angioedema in three brothers with normal C1 esterase inhibitor level and function. Allergy 2004; 59: 557-558
34. Bork K, Gul D, Dewald G. Hereditary angio-oedema with normal C1 inhibitor in a family with affected women and men. Br J Dermatol 2006; 154: 542-545
35. Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore) 1992; 71: 206-215
36. Frank MM. Hereditary angioedema: the clinical syndrome and its management in the United States. Immunol Allergy Clin North Am 2006; 26: 653-668
37. Bork K, Staubach P, Eckardt AJ, et al. Symptoms, course, and complications of abdominal attacks in hereditary angioedema due to C1 inhibitor deficiency. Am J Gastroenterol 2006; 101: 619-627
38. Donaldson VH, Rosen FS. Hereditary angioneurotic edema: a clinical survey. Pediatrics 1966; 37: 1017-1027
39. Ohela K. Hereditary angioneurotic oedema in Finland: clinical, immunological and genealogical studies. Acta Med Scand 1977; 201: 415-427
40. Zeana C. Hereditary angioedema due to deficit of C1 esterase inhibitor. Med Interne 1989; 27: 143-147
41. Frank MM. Hereditary angioedema. Curr Opin Pediatr 2005; 17: 686-689
42. Boyle RJ, Nikpour M, Tang ML. Hereditary angio-oedema in children: a management guideline. Pediatr Allergy Immunol 2005; 16: 288-294
43. Bork K, Meng G, Staubach P, et al. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med 2006; 119: 267-274
44. Farkas H, Varga L, Szeplaki G, et al. Management of hereditary angioedema in pediatric patients. Pediatrics 2007; 120: 713-722
45. Farkas H, Jakab L, Temesszentandrasi G, et al. Hereditary angioedema: a decade of human C1-inhibitor concentrate therapy. J Allergy Clin Immunol 2007; 120: 941-947
46. Sanchez A, Ecochard A, Maestracci M, et al. Hereditary angioedema causing colocolic intussusception. Arch Pediatr 2008; 15: 271-274
47. Frank MM, Gelfand JA, Atkinson JP. Hereditary angioedema: the clinical syndrome and its management. Ann Intern Med 1976; 84: 580-593
48. Cicardi M, Bergamaschini L, Marasini B, et al. Hereditary angioedema: an appraisal of 104 cases. Am J Med Sci 1982; 284: 2-9
49. Sim TC, Grant JA. Hereditary angioedema: its diagnostic and management perspectives. Am J Med 1990; 88: 656-664
50. Winnewisser J, Rossi M, Spath P, et al. Type I hereditary angio-oedema: variability of clinical presentation and course within two large kindreds. J Intern Med 1997; 241: 39-46
51. Sofia S, Casali A, Bolondi L. Sonographic findings in abdominal hereditary angioedema. J Clin Ultrasound 1999; 27: 537-540
52. Shah TJ, Knowles WO, McGeady SJ. Hereditary angioedema with recurrent abdominal pain and ascites. J Allergy Clin Immunol 1995; 96: 259-261
53. De Backer AI, De Schepper AM, Vandevenne JE, et al. CT of angioedema of the small bowel. Am J Roentgenol 2001; 176: 649-652
54. Sunder TR, Balsam MJ, Vengrow MI. Neurological manifestations of angioedema: report of two cases and review of the literature. JAMA 1982; 247: 2005-2007
55. Neri S, Ierna D, Sfogliano L. Unusual manifestations of hereditary angioedema. Eur J Emerg Med 2000; 7: 111-112
56. Van Dellen RC, Myers RP. Bladder involvement in hereditary angioedema. Mayo Clin Proc 1980; 55: 277-278
57. De Knop KJ, Hagendorens MM, Stevens WJ, et al. Angioedema beyond histamine: an educational case series. Acta Clin Belg 2009; 64: 520-528
58. Brickman CM, Tsokos GC, Balow JE, et al. Immunoregulatory disorders associated with hereditary angioedema: I. Clinical manifestations of autoimmune disease. J Allergy Clin Immunol 1986; 77: 749-757
59. Carugati A, Pappalardo E, Zingale LC, et al. C1-inhibitor deficiency and angioedema. Mol Immunol 2001; 38: 161-173
60. Zingale LC, Beltrami L, Zanichelli A, et al. Angioedema without urticaria: a large clinical survey. CMAJ 2006; 175: 1065-1070
61. Roche O, Blanch A, Caballero T, et al. Hereditary angioedema due to C1 inhibitor deficiency: patient registry and approach to the prevalence in Spain. Ann Allergy Asthma Immunol 2005; 94: 498-503
62. Pappalardo E, Cicardi M, Duponchel C, et al. Frequent de novo mutations and exon deletions in the C1 inhibitor gene of patients with angioedema. J Allergy Clin Immunol 2000; 106: 1147-1154
63. Bailey E, Shaker M. An update on childhood urticaria and angioedema. Curr Opin Pediatr 2008; 20: 425-430
64. Novembre E, Cianferoni A, Mori F, et al. Urticaria and urticaria related skin condition/disease in children. Eur Ann Allergy Clin Immunol 2008; 40: 5-13
65. Krishnamurthy A, Naguwa SM, Gershwin ME. Pediatric angioedema. Clin Rev Allergy Immunol 2008; 34: 250-259
66. Quastel M, Harrison R, Cicardi M, et al. Behavior in vivo of normal and dysfunctional C1 inhibitor in normal subjects and patients with hereditary angioneurotic edema. J Clin Invest 1983; 71: 1041-1046
67. Gompels MM, Lock RJ, Morgan JE, et al. A multicentre evaluation of the diagnostic efficiency of serological investigations for C1 inhibitor deficiency. J Clin Pathol 2002; 55: 145-147
68. Karim Y, Griffiths H, Deacock S. Normal complement C4 values do not exclude hereditary angioedema. J Clin Pathol 2004; 57: 213-214
69. Tarzi MD, Hickey A, Forster T, et al. An evaluation of tests used for the diagnosis and monitoring of C1 inhibitor deficiency: normal serum C4 does not exclude hereditary angio-oedema. Clin Exp Immunol 2007; 149: 513-516
70. Davis CA, Vallota EH, Forristal J. Serum complement levels in infancy: age related changes. Pediatr Res 1979; 13: 1043-1046
71. Lockitch G, Halstead AC, Quigley G, et al. Age-and sex-specific pediatric reference intervals: study design and methods illustrated by measurement of serum proteins with the Behring LN Nephelometer. Clin Chem 1988; 34: 1618-1621
72. Roach B, Kim Y, Jerome E, et al. Influence of age and sex on serum complement components in children. Am J Dis Child 1981; 135: 918-920
73. Nielsen EW, Johansen HT, Holt J, et al. C1 inhibitor and diagnosis of hereditary angioedema in newborns. Pediatr Res 1994; 35: 184-187
74. Bowen T, Cicardi M, Bork K, et al. Hereditary angiodema: a current state-of-the-art review: VII. Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. Ann Allergy Asthma Immunol 2008; 100: S30-40
75. Jackson J, Sim RB, Whelan A, et al. An IgG autoantibody which inactivates C1-inhibitor. Nature 1986; 323: 722-724
76. Alsenz J, Bork K, Loos M. Autoantibody-mediated acquired deficiency of C1 inhibitor. N Engl J Med 1987; 316: 1360-1366
77. Cicardi M, Beretta A, Colombo M, et al. Relevance of lymphoproliferative disorders and of anti-C1 inhibitor autoantibodies in acquired angio-oedema. Clin Exp Immunol 1996; 106: 475-480
78. Cicardi M, Zingale LC, Pappalardo E, et al. Autoantibodies and lymphoproliferative diseases in acquired C1-inhibitor deficiencies. Medicine (Baltimore) 2003; 82: 274-281
79. Donaldson VH, Wagner CJ, Davis III AE. An autoantibody to C1-inhibitor recognizes the reactive centerofthe inhibitor.JLab Clin Med 1996; 127: 229-232
80. Varga L, Szeplaki G, Visy B, et al. C1-inhibitor (C1-INH) autoantibodies in hereditary angioedema: strong correlation with the severity of disease in C1-INH concentrate naive patients. Mol Immunol 2007; 44: 1454-1460
81. Zuraw BL. Hereditary angioedema. N Engl J Med 2008; 359: 1027-1036
82. Farkas H, Harmat G, Kaposi PN, et al. Ultrasonography in the diagnosis and monitoring ofascites in acute abdominal attacks of hereditary angioneurotic oedema. Eur J Gastroenterol Hepatol 2001; 13: 1225-1230
83. Gadek JE, Hosea SW, Gelfand JA, et al. Replacement therapy in hereditary angioedema: successful treatment of acute episodes of angioedema with partly purified C1 inhibitor. N Engl J Med 1980; 302: 542-546
84. Phillips M. C1-inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 1980; 303: 526-527
85. Waytes AT, Rosen FS, Frank MM. Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N Engl J Med 1996; 334: 1630-1634
86. Kunschak M, Engl W, Maritsch F, et al. A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema. Transfusion 1998; 38: 540-549
87. Visentin DE, Yang WH, Karsh J. C1-esterase inhibitor transfusions in patients with hereditary angioedema. Ann Allergy Asthma Immunol 1998; 80: 457-461
88. Bork K, Barnstedt SE. Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema. Arch Intern Med 2001; 161: 714-718
89. de Serres J, Groner A, Lindner J. Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert P) in hereditary angioedema: a review. Transfus Apher Sci 2003; 29: 247-254
90. Bork K, Meng G, Staubach P, et al. Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema. Transfusion 2005; 45: 1774-1784
91. Levi M, Choi G, Picavet C, et al. Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency. J Allergy Clin Immunol 2006; 117: 904-908
92. Longhurst HJ, Carr S, Khair K. C1-inhibitor concentrate home therapy for hereditary angioedema: a viable, effective treatment option. Clin Exp Immunol 2007; 147: 11-17
93. Bork K, Barnstedt SE. Laryngeal edema and death from asphyxiation after tooth extraction in four patients with hereditary angioedema. J Am Dent Assoc 2003; 134: 1088-1094
94. Pickering RJ, Good RA, Kelly JR, et al. Replacement therapy in hereditary angioedema: successful treatment of two patients with fresh frozen plasma. Lancet 1969; 1: 326-330
95. Hill BJ, Thomas SH, McCabe C. Fresh frozen plasma for acute exacerbations of hereditary angioedema [letter]. Am J Emerg Med 2004; 22: 633
96. Prematta M, Gibbs JG, Pratt EL, et al. Fresh frozen plasma for the treatment of hereditary angioedema. Ann Allergy Asthma Immunol 2007; 98: 383-388
97. Pekdemir M, Ersel M, Aksay E, et al. Effective treatment of hereditary angioedema with fresh frozen plasma in an emergency department. J Emerg Med 2007; 33: 137-139
98. Dingle JT, Gordon J. Research monographs in cell and tissue physiology: proteinase inhibitors. Cambridge: Elsevier, 1988
99. Williams A, Baird LG. DX-88 and HAE: a developmental perspective. Transfus Apher Sci 2003; 29: 255-258
100. Levy JH, O'Donnell PS. The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema. Expert Opin Investig Drugs 2006; 15: 1077-1090
101. Frank MM. Hereditary angioedema. J Allergy Clin Immunol 2008; 121 Suppl.: S398-401
102. van Doorn MB, Burggraaf J, van DT, et al. A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. J Allergy Clin Immunol 2005; 116: 876-883
103. Koles K, van Berkel PH, Pieper FR, et al. N-and O-glycans of recombinant human C1 inhibitor expressed in the milk of transgenic rabbits. Glycobiology 2004; 14: 51-64
104. Longhurst H. Rhucin, a recombinant C1 inhibitor for the treatment of hereditary angioedema and cerebral ischemia. Curr Opin Investig Drugs 2008; 9: 310-323
105. Atkinson JC, Frank MM. Oral manifestations and dental management of patients with hereditary angioedema. J Oral Pathol Med 1991; 20: 139-142
106. Maeda S, Miyawaki T, Nomura S, et al. Management of oral surgery in patients with hereditary or acquired angioedemas: review and case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003; 96: 540-543
107. Jaffe CJ, Atkinson JP, Gelfand JA, et al. Hereditary angioedema: the use of fresh frozen plasma for prophylaxis in patients undergoing oral surgery. J Allergy Clin Immunol 1975; 55: 386-393
108. Spaulding WB. Methyltestosterone therapy for hereditary episodic edema (hereditary angioneurotic edema). Ann Intern Med 1960; 53: 739-745
109. Sheffer AL, Fearon DT, Austen KF. Clinical and biochemical effects of impeded androgen (oxymetholone) therapy of hereditary angioedema. J Allergy Clin Immunol 1979; 64: 275-280
110. Gelfand JA, Sherins RJ, Alling DW, et al. Treatment of hereditary angioedema with danazol: reversal of clinical and biochemical abnormalities. N Engl J Med 1976; 295: 1444-1448
111. Agostoni A, Cicardi M, Bergamaschini L, et al. C1-inhibitor concentrate for treatment of hereditary angioedema [letter]. N Engl J Med 1980; 303: 527
112. Sheffer AL, Fearon DT, Austen KF. Clinical and biochemical effects of stanozolol therapy for hereditary angioedema. J Allergy Clin Immunol 1981; 68: 181-187
113. Cicardi M, Bergamaschini L, Tucci A, et al. Morphologic evaluation of the liver in hereditary angioedema patients on long-term treatment with androgen derivatives. J Allergy Clin Immunol 1983; 72: 294-298
114. Sheffer AL, Fearon DT, Austen KF. Hereditary angioedema: a decade of management with stanozolol. J Allergy Clin Immunol 1987; 80: 855-860
115. Cicardi M, Castelli R, Zingale LC, et al. Side effects of long-term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patients. J Allergy Clin Immunol 1997; 99: 194-196
116. Szeplaki G, Varga L, Valentin S, et al. Adverse effects of danazol prophylaxis on the lipid profiles of patients with hereditary angioedema. J Allergy Clin Immunol 2005; 115: 864-869
117. Sloane DE, Lee CW, Sheffer AL. Hereditary angioedema: safety of long-term stanozolol therapy. J Allergy Clin Immunol 2007; 120: 654-658
118. Pappalardo E, Zingale LC, Cicardi M. Increased expression of C1-inhibitor mRNA in patients with hereditary angioedema treated with danazol. Immunol Lett 2003; 86: 271-276
119. Bork K,PittonM, Harten P, etal. Hepatocellular adenomas inpatients taking danazol for hereditary angio-oedema. Lancet 1999; 353: 1066-1067
120. Bork K, Schneiders V. Danazol-induced hepatocellular adenoma in patients with hereditary angio-oedema. J Hepatol 2002; 36: 707-709
121. Shahidi NT. A review of the chemistry, biological action, and clinical applications of anabolic-androgenic steroids. Clin Ther 2001; 23: 1355-1390
122. Church JA. Oxandrolone treatment of childhood hereditary angioedema. Ann Allergy Asthma Immunol 2004; 92: 377-378
123. Frank MM, Sergent JS, Kane MA, et al. Epsilon aminocaproic acid therapy of hereditary angioneurotic edema: a double-blind study. N Engl J Med 1972; 286: 808-812
124. Sheffer AL, Austen KF, Rosen FS. Tranexamic acid therapy in hereditary angioneurotic edema. N Engl J Med 1972; 287: 452-454